Ozempic vs. Wegovy vs. Mounjaro: Real Results After 60 Days (2026)

Key Takeaways

• Mounjaro produced the highest average weight loss in clinical trials, reaching up to 22.5% over 72 weeks.
• Wegovy users lost an average of 14.9% of body weight in the STEP 1 trial.
• Ozempic users typically lose around 12–14% of body weight.
• Mounjaro generally produces greater A1C reductions than Ozempic.
• Digestive side effects are common with all three medications.
• Berberine may support blood sugar control, but it does not match GLP-1 drugs for weight loss.

You have probably seen people online talking about dramatic weight loss with Ozempic, Wegovy, or Mounjaro. But the results, side effects, and costs are not identical, and choosing the right option is not as simple as social media makes it seem.

Clinical trials show that all three medications can be effective, but they differ in weight loss results, blood sugar control, side effects, and price. Here's what the research shows.

In this guide, we compare the results, side effects, and costs of all three drugs and examine where natural options like berberine fit in. 

What Are These Three Drugs, Really?

All three medications belong to the GLP-1 family. This class of drugs helps regulate appetite, slow digestion, and improve blood sugar control. However, they are not identical.

Ozempic contains semaglutide and is FDA-approved for type 2 diabetes. In addition to lowering blood sugar, it has also been shown to reduce cardiovascular risk.

Wegovy contains the same active ingredient, semaglutide, but at a higher maximum dose. It is FDA-approved specifically for chronic weight management and cardiovascular risk reduction in adults with obesity.

Mounjaro contains tirzepatide and works differently by activating both GLP-1 and GIP receptors. This dual mechanism is believed to contribute to its stronger weight loss effects seen in clinical trials.

Drug Comparison

Which Drug Produces the Most Weight Loss?

All three medications can produce meaningful weight loss, but the results are not identical.

Clinical trials consistently show that Mounjaro delivers the greatest average weight loss, followed by Wegovy and then Ozempic.

1. Ozempic

Ozempic is FDA-approved for type 2 diabetes, not chronic weight management. Weight loss can happen, but it is considered a secondary effect, and results are generally more modest than with Wegovy or Mounjaro.

In clinical trials of Ozempic, adults using the 1 mg dose lost about 7.7 lb more than placebo, while A1C dropped by about 1.6 percentage points in one trial.

2. Wegovy

Wegovy uses the same active ingredient as Ozempic, but at a higher dose.

In the STEP 1 trial published in the New England Journal of Medicine, participants lost an average of 14.9% of their body weight after 68 weeks. Some patients achieved weight loss exceeding 15–17%.

Researchers later found that Wegovy also reduced the risk of major cardiovascular events, leading to an additional FDA approval.

3. Mounjaro

Mounjaro produced the strongest results across both blood sugar and weight loss studies.

In the SURMOUNT trials, participants achieved up to 22.5% average body weight loss after 72 weeks. Mounjaro also lowered A1C by approximately 1.8–2.4% in the SURPASS trials.

Average Weight Loss Comparison

Side Effects: What Nobody Warns You About 

All three medications work by slowing stomach emptying. That helps reduce appetite, but it also explains why digestive side effects are common, especially during the first few weeks.

Most symptoms improve over time, but some people stop treatment because of them.

1. Gastrointestinal Side Effects

For Ozempic, nausea affected about 15.8% of patients at the 0.5 mg dose and 20.3% at the 1 mg dose. Diarrhea occurred in roughly 9% of patients, while vomiting and constipation were less common.

Mounjaro tends to cause more digestive side effects. Across the SURPASS trials, gastrointestinal symptoms occurred in 37–44% of patients depending on the dose. At the highest 15 mg dose, 6.6% of patients discontinued treatment because of side effects.

2. Common Side Effects

• nausea
• diarrhea
• constipation
• vomiting
• abdominal pain
• fatigue
• decreased appetite

3. Serious but Less Common Risks

Serious complications are uncommon, but they can occur with all three medications.

Potential risks include:

• pancreatitis
• gallbladder disease
• acute kidney injury
• worsening diabetic retinopathy
• thyroid C-cell tumor warning based on rodent studies

Although uncommon, these risks should be discussed with your doctor before starting treatment.

How Much Do Ozempic, Wegovy, and Mounjaro Cost? 

Cost is one of the biggest barriers for many people considering GLP-1 medications.

Monthly Cost Without Insurance

With Commercial Insurance and Savings Programs

Manufacturer savings cards can dramatically lower out-of-pocket costs for eligible patients.

Commercially insured patients may pay as little as $25 per month for Ozempic, Wegovy, or Mounjaro through their respective savings programs.

These programs generally do not apply to Medicare, Medicaid, or uninsured patients.

Annual Cost Adds Up Quickly

Without insurance, yearly treatment costs can exceed:

• $12,000 for Ozempic
• $16,000 for Wegovy
• $13,000–$16,000 for Mounjaro

This is one reason why long-term affordability becomes an important part of the decision.

What Happens to Your Weight When You Stop GLP-1 Medications? 

One of the biggest misconceptions about Ozempic, Wegovy, and Mounjaro is that the weight loss is permanent. In reality, studies show that a significant amount of weight can return after treatment stops.

A STEP 1 extension study found that participants regained approximately two-thirds of their lost weight within one year after stopping treatment.

Several factors contribute to weight regain:

• appetite gradually returns to pre-treatment levels
• metabolism slows after weight loss
• muscle mass may decline during rapid weight loss
• old eating habits often return
• physical activity levels may decrease

These findings highlight that obesity is a chronic condition requiring long-term management.

After stopping therapy, it becomes especially important to focus on:

• regular exercise
• healthy  eating habits
• adequate protein intake
• blood sugar support

becomes especially important after stopping therapy.

What Actually Happens During the First 60 Days? 

The exact experience varies from person to person, but clinical trials and real-world reports show several common patterns. 

1. Days 1–14: Dose Titration Begins

Side effects are usually most noticeable during the first two weeks as the body adapts to treatment.

Common experiences include:

• nausea
• reduced appetite
• early fullness
• fatigue
• smaller meal portions
• less interest in food

Clinical trials found that nausea affected about 16–20% of Ozempic users, making it the most common side effect. Around 3–7% of patients discontinue treatment because of intolerance.

2. Days 15–30: The Body Starts Adjusting

By the third and fourth weeks, digestive symptoms often begin to improve.

Many people report:

• fewer cravings
• better portion control
• improving blood sugar readings
• gradual weight loss
• more stable eating patterns

The SURPASS and STEP programs showed that early weight loss and glycemic improvements begin within the first several weeks, although maximum benefits occur much later.

3. Days 31–60: Stabilization

By the second month, many patients experience fewer side effects and more consistent progress.

Common patterns include:

• continued weight loss
• improved fasting glucose levels
• smaller meal sizes becoming routine
• better appetite control
• improving A1C trends

Patients using higher-dose tirzepatide often report more dramatic results during this period, although full clinical outcomes are measured over much longer periods.

Bottom Line

Ozempic, Wegovy, and Mounjaro are all effective medications, but they are designed for different goals.

Clinical trials consistently show that Mounjaro delivers the greatest weight loss, while Wegovy remains one of the most established options for obesity treatment. Ozempic continues to be a strong choice for people whose primary focus is type 2 diabetes and cardiovascular protection.

Frequently Asked Questions

Is Wegovy stronger than Ozempic?

For weight loss, yes. Both drugs contain semaglutide, but Wegovy uses a higher maximum dose of 2.4 mg and is specifically approved for chronic weight management.

Is Mounjaro better than Wegovy?

Clinical trials suggest that Mounjaro produces greater weight loss. In the SURMOUNT-5 trial, tirzepatide resulted in approximately 20% weight loss compared with about 14% for semaglutide.

Do you gain weight back after stopping Ozempic, Wegovy, or Mounjaro?

Yes. Studies show that a significant portion of lost weight is regained after treatment stops. Participants in the STEP 1 extension study regained about two-thirds of their lost weight within one year.

Can you switch from Ozempic to Mounjaro?

Yes, but the transition should always be supervised by a healthcare provider. Factors such as blood sugar control, side effects, and dosing schedules need to be considered.